open access

Vol 15, No 3 (2019)
Research paper
Published online: 2019-06-26
Get Citation

Vismodegib in the treatment of basal cell carcinoma — Polish clinical experience in the frame of therapeutic program

Monika Słowińska, Aldona Maciąg, Monika Dudzisz-Śledź, Izabela Łasińska, Tomasz Świtaj, Hanna Koseła-Paterczyk, Aleksandra Bolewska, Katarzyna Wróbel, Paweł Golusiński, Jacek Mackiewicz, Piotr Rutkowski, Witold Owczarek
DOI: 10.5603/OCP.2018.0041
·
Oncol Clin Pract 2019;15(3):139-149.

open access

Vol 15, No 3 (2019)
ORIGINAL ARTICLE
Published online: 2019-06-26

Abstract

Introduction. Vismodegib is a small-molecule inhibitor of the sonic hedgehog pathway, registered for the treat- ment of patients with metastatic or locally advanced basal cell carcinoma, who were disqualified from surgical excision or radiotherapy. The full treatment refund from the National Health Fund has been available in Poland since 1st January 2018. The aim of the study was to analyse the frequency of occurrence of adverse events based on CTCAE and the treatment results based on the RECIST 1.1 criteria, in a group of patients treated for six or 12 months with vismodegib. 

Material and methods. The patient database was gathered from three sites and consisted of 42 patients, who represented 53.8% of the patients treated with vismodegib in Poland. The duration of the treatment ranged between three weeks and 68 months. The median of the treatment period was 8.25 months (0.75–68); the median of the observation of patients treated for less than 12 months was eight months (6–11), and for those treated for more than 12 months it was 14 months (12–68). 

Results. The summary of the treatment results after six and 12 months was performed on 29/42 and 17/42 patients accordingly. Complete response was achieved in 3/29 (10.3%) and 3/16 (17.6%) patients after six and 12 months of treatment, respectively, partial response in 13/29 (44.8%) and 5/16 (29.4%) patients, respectively, and stable disease in 13/29 (44.8%) and 8/16 (50.0%) patients, respectively. Progression of the disease was experienced by 7/42 (16.6%) patients within the period of 3–28 months of treatment. One patient with brain metastases died due to the progression of the disease. Adverse events were reported in 31/42 (73.8%) patients, more than one adverse event in a single patient was reported in 22/42 (52.3%) patients. No serious adverse events were observed. 

Abstract

Introduction. Vismodegib is a small-molecule inhibitor of the sonic hedgehog pathway, registered for the treat- ment of patients with metastatic or locally advanced basal cell carcinoma, who were disqualified from surgical excision or radiotherapy. The full treatment refund from the National Health Fund has been available in Poland since 1st January 2018. The aim of the study was to analyse the frequency of occurrence of adverse events based on CTCAE and the treatment results based on the RECIST 1.1 criteria, in a group of patients treated for six or 12 months with vismodegib. 

Material and methods. The patient database was gathered from three sites and consisted of 42 patients, who represented 53.8% of the patients treated with vismodegib in Poland. The duration of the treatment ranged between three weeks and 68 months. The median of the treatment period was 8.25 months (0.75–68); the median of the observation of patients treated for less than 12 months was eight months (6–11), and for those treated for more than 12 months it was 14 months (12–68). 

Results. The summary of the treatment results after six and 12 months was performed on 29/42 and 17/42 patients accordingly. Complete response was achieved in 3/29 (10.3%) and 3/16 (17.6%) patients after six and 12 months of treatment, respectively, partial response in 13/29 (44.8%) and 5/16 (29.4%) patients, respectively, and stable disease in 13/29 (44.8%) and 8/16 (50.0%) patients, respectively. Progression of the disease was experienced by 7/42 (16.6%) patients within the period of 3–28 months of treatment. One patient with brain metastases died due to the progression of the disease. Adverse events were reported in 31/42 (73.8%) patients, more than one adverse event in a single patient was reported in 22/42 (52.3%) patients. No serious adverse events were observed. 

Get Citation

Keywords

vismodegib; basal cell carcinoma; treatment response rate; adverse events

About this article
Title

Vismodegib in the treatment of basal cell carcinoma — Polish clinical experience in the frame of therapeutic program

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 3 (2019)

Article type

Research paper

Pages

139-149

Published online

2019-06-26

DOI

10.5603/OCP.2018.0041

Bibliographic record

Oncol Clin Pract 2019;15(3):139-149.

Keywords

vismodegib
basal cell carcinoma
treatment response rate
adverse events

Authors

Monika Słowińska
Aldona Maciąg
Monika Dudzisz-Śledź
Izabela Łasińska
Tomasz Świtaj
Hanna Koseła-Paterczyk
Aleksandra Bolewska
Katarzyna Wróbel
Paweł Golusiński
Jacek Mackiewicz
Piotr Rutkowski
Witold Owczarek

References (18)
  1. Krajowy Rejestr Nowotworów - http://onkologia. org pl/nowotwory-skory-c44.
  2. Flohil SC, de Vries E, Neumann HA, et al. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011; 91(1): 24–30.
  3. Bichakjian CK, Alam M, Kim JYS, et al. Work Group, Invited Reviewers. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018; 78(3): 540–559.
  4. Sekulic A, et al. Migden MR, Oro AE. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, N Engl J Med. 2012; 366: 2171–9.
  5. Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. The Lancet Oncology. 2015; 16(6): 729–736.
  6. Wismodegib - Charakterystyka produktu leczniczego. https://www.roche.pl/content/dam/roche_poland_rwd/pl_PL/documents/SmPC/erivedge.pdf.
  7. Eastern Cooperative Oncology Group (ECOG) http://www.npcrc.org/files/news/ECOG_performance_status.pdf.
  8. Załącznik B. 88. do programu leczenia zaawansowanego raka podstawnokomórkowego wismodegibem. http://onkologia-online pl/upload/obwieszczenie/2016 12 28/b/b. ; 88: pdf.
  9. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 U.S. Department Of Health And Human Services https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
  10. Płużański A. Kryteria oceny odpowiedzi na leczenie RECIST 1.1. Nowotwory. Journal of Oncology. 2014; 64(4): 331–335.
  11. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70(1): 60–69.
  12. Lacouture M, Guillen J, Kudchadkar R, et al. 3341 The RegiSONIC Disease Registry Study: Safety and effectiveness of vismodegib or surgery as primary treatment in patients with locally advanced basal cell carcinoma. European Journal of Cancer. 2015; 51: S679–S680.
  13. Chang AL, Arron ST, Migden MR, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016; 11(1): 120.
  14. Sekulic A, Migden MR, Basset-Seguin N, et al. ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017; 17(1): 332.
  15. Zhao J, Quan H, Xie C, et al. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharmacol Res Perspect. 2014; 2(3): e00043.
  16. Kwon GP, Ally MS, Bailey-Healy I, et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016; 75(1): 213–215.
  17. Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014; 70(4): e88–e89.
  18. Rutkowski P, Owczarek W. (eds). Skin carcinomas. Oncol Clin Pract. 2018; 14(3): 129–147.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl